Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

338 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state.
Shakir KM, Kroll S, Aprill BS, Drake AJ 3rd, Eisold JF. Shakir KM, et al. Among authors: kroll s. Mayo Clin Proc. 1995 Jun;70(6):556-8. doi: 10.4065/70.6.556. Mayo Clin Proc. 1995. PMID: 7776715 Clinical Trial.
Angiotensin II for the Treatment of Vasodilatory Shock.
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Khanna A, et al. Among authors: kroll s. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. N Engl J Med. 2017. PMID: 28528561 Clinical Trial.
Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
Abril MK, Khanna AK, Kroll S, McNamara C, Handisides D, Busse LW. Abril MK, et al. Among authors: kroll s. J Crit Care. 2019 Apr;50:188-194. doi: 10.1016/j.jcrc.2018.12.007. Epub 2018 Dec 8. J Crit Care. 2019. PMID: 30553989
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.
Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Tumlin JA, et al. Among authors: kroll s. Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092. Crit Care Med. 2018. PMID: 29509568 Free PMC article.
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Tap WD, et al. Among authors: kroll s. Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Lancet Oncol. 2017. PMID: 28651927 Free PMC article. Clinical Trial.
The authors reply.
Bellomo R, Kroll S, Chawla LS, Tidmarsh GF. Bellomo R, et al. Among authors: kroll s. Crit Care Med. 2019 Mar;47(3):e271-e272. doi: 10.1097/CCM.0000000000003601. Crit Care Med. 2019. PMID: 30768522 No abstract available.
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Borad MJ, et al. Among authors: kroll s. J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512461 Free PMC article. Clinical Trial.
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP. Ganjoo KN, et al. Among authors: kroll s. Oncology. 2011;80(1-2):50-6. doi: 10.1159/000327739. Epub 2011 May 31. Oncology. 2011. PMID: 21625179 Clinical Trial.
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302.
Weiss GJ, Lewandowski K, Oneall J, Kroll S. Weiss GJ, et al. Among authors: kroll s. Dermatol Reports. 2011 Dec 1;3(3):e56. doi: 10.4081/dr.2011.e56. eCollection 2011 Oct 5. Dermatol Reports. 2011. PMID: 25386307 Free PMC article.
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Badar T, et al. Among authors: kroll s. Am J Hematol. 2016 Aug;91(8):800-5. doi: 10.1002/ajh.24415. Epub 2016 Jun 25. Am J Hematol. 2016. PMID: 27169385 Free PMC article. Clinical Trial.
338 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback